Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab plus atorvastatin versus atorvastatin alone for thin-cap fibroatheroma in very high-risk ASCVD
ChiCTR2000032570Phase 4Recruiting
- Sponsor
- Chinese Cardiovascular Association
- Start
- May 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of evolocumab and atorvastatin in atherosclerotic disease (2 arms), sponsored by Chinese Cardiovascular Association. Primary endpoint: Fiber cap thickness of TCFA. Started May 2020; status: recruiting.
02
Drugs
evolocumabatorvastatin
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on ChiCTR2000032570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032570.